FR14C0049I2 - Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive - Google Patents

Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive

Info

Publication number
FR14C0049I2
FR14C0049I2 FR14C0049C FR14C0049C FR14C0049I2 FR 14C0049 I2 FR14C0049 I2 FR 14C0049I2 FR 14C0049 C FR14C0049 C FR 14C0049C FR 14C0049 C FR14C0049 C FR 14C0049C FR 14C0049 I2 FR14C0049 I2 FR 14C0049I2
Authority
FR
France
Prior art keywords
treatment
chronic obstructive
new drugs
obstructive bronchopneumopathy
bronchopneumopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0049C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of FR14C0049I1 publication Critical patent/FR14C0049I1/fr
Application granted granted Critical
Publication of FR14C0049I2 publication Critical patent/FR14C0049I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR14C0049C 2002-11-15 2014-06-23 Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive Active FR14C0049I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (2)

Publication Number Publication Date
FR14C0049I1 FR14C0049I1 (cs) 2014-08-08
FR14C0049I2 true FR14C0049I2 (fr) 2015-07-24

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0049C Active FR14C0049I2 (fr) 2002-11-15 2014-06-23 Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive

Country Status (38)

Country Link
EP (2) EP2025338A1 (cs)
JP (1) JP4317138B2 (cs)
KR (1) KR101092247B1 (cs)
CN (3) CN1713914A (cs)
AR (2) AR041969A1 (cs)
AT (1) ATE430569T1 (cs)
AU (1) AU2003285326B2 (cs)
BE (1) BE2014C016I2 (cs)
BR (1) BRPI0316264B8 (cs)
CA (1) CA2506082C (cs)
CO (1) CO5570670A2 (cs)
CY (2) CY1110500T1 (cs)
DE (2) DE10253282A1 (cs)
DK (1) DK1562603T3 (cs)
EA (1) EA008665B1 (cs)
EC (1) ECSP055774A (cs)
ES (1) ES2326878T7 (cs)
FR (1) FR14C0049I2 (cs)
HR (1) HRP20050432B1 (cs)
HU (1) HUS1400011I1 (cs)
IL (1) IL167900A (cs)
LT (1) LTC1562603I2 (cs)
LU (1) LU92433I2 (cs)
ME (1) ME00354B (cs)
MX (1) MXPA05005081A (cs)
MY (1) MY136034A (cs)
NL (1) NL300650I2 (cs)
NO (2) NO334314B1 (cs)
NZ (1) NZ540661A (cs)
PE (1) PE20040694A1 (cs)
PL (1) PL212238B1 (cs)
PT (1) PT1562603E (cs)
RS (1) RS51607B (cs)
SI (1) SI1562603T1 (cs)
TW (1) TWI343812B (cs)
UA (1) UA81276C2 (cs)
WO (1) WO2004045618A2 (cs)
ZA (1) ZA200502246B (cs)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
JP2007533683A (ja) * 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患治療用のベンゾオキサジン含有医薬組成物
WO2005110990A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
WO2007017670A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
PL1917253T3 (pl) * 2005-08-15 2015-06-30 Boehringer Ingelheim Int Sposób wytwarzania betamimetyków
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
KR20080067699A (ko) * 2005-11-09 2008-07-21 베링거 인겔하임 인터내셔날 게엠베하 흡입용 에어로졸 제형
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
JP5373599B2 (ja) 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
CA2660192A1 (en) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Novel enantiomeric pure beta agonists, method of manufacture and use as a medicament thereof
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
EP2104535B9 (en) 2007-01-10 2011-06-15 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR101456872B1 (ko) * 2007-01-25 2014-10-31 베링거 인겔하임 인터내셔날 게엠베하 베타미메틱의 제조방법
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
TWI439462B (zh) 2007-12-10 2014-06-01 Novartis Ag 作為ｅｎａｃ阻抑劑之螺環胍化合物
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
CN102112130A (zh) 2008-06-10 2011-06-29 诺瓦提斯公司 作为上皮钠通道阻滞剂的吡嗪衍生物
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
MX390695B (es) * 2010-09-21 2025-03-21 Intekrin Therapeutics Inc Composiciones farmaceuticas solidas antidiabeticas
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
EP3134395B1 (en) 2014-04-24 2018-01-31 Novartis AG Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
ES2900283T3 (es) 2016-12-20 2022-03-16 Inke Sa Proceso mejorado para la fabricación de clorhidrato de (R)-6-hidroxi-8-[1-hidroxi-2-[2-(4-metoxifenil)-1,1-dimetiletilaminoetil]-2H-1,4-benzoxazin-3(4H)-ona
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
CN115768404B (zh) * 2020-06-09 2024-11-08 广州谷森制药有限公司 含乌美溴铵和三苯乙酸维兰特罗的药物制剂
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
HRP20020845A2 (en) * 2000-04-27 2003-10-31 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments

Also Published As

Publication number Publication date
TW200423943A (en) 2004-11-16
UA81276C2 (en) 2007-12-25
KR101092247B1 (ko) 2011-12-12
AR087241A2 (es) 2014-03-12
CY2014032I1 (el) 2015-12-09
MEP53608A (en) 2011-05-10
CY2014032I2 (el) 2015-12-09
LU92433I2 (fr) 2014-06-24
FR14C0049I1 (cs) 2014-08-08
BRPI0316264B1 (pt) 2019-04-09
RS20050361A (sr) 2007-04-10
CN1713914A (zh) 2005-12-28
EP1562603B1 (de) 2009-05-06
TWI343812B (en) 2011-06-21
CA2506082A1 (en) 2004-06-03
NO2014005I1 (no) 2014-03-10
RS51607B (sr) 2011-08-31
EA008665B1 (ru) 2007-06-29
DK1562603T3 (da) 2009-09-07
JP2006508140A (ja) 2006-03-09
HUS1400011I1 (hu) 2022-02-28
NZ540661A (en) 2007-12-21
CN101735166A (zh) 2010-06-16
EP2025338A1 (de) 2009-02-18
SI1562603T1 (sl) 2009-10-31
ATE430569T1 (de) 2009-05-15
EP1562603A2 (de) 2005-08-17
BR0316264A (pt) 2005-10-11
EP1562603B3 (de) 2014-01-08
ES2326878T3 (es) 2009-10-21
HRP20050432B1 (en) 2012-01-31
AR041969A1 (es) 2005-06-01
PL212238B1 (pl) 2012-08-31
ES2326878T7 (es) 2014-03-11
NO334314B1 (no) 2014-02-03
PE20040694A1 (es) 2004-11-23
PL375270A1 (en) 2005-11-28
AU2003285326B2 (en) 2009-06-04
CN101817800A (zh) 2010-09-01
NO20052883L (no) 2005-06-14
ME00354B (me) 2011-10-10
JP4317138B2 (ja) 2009-08-19
WO2004045618A3 (de) 2004-09-30
ZA200502246B (en) 2006-01-25
MY136034A (en) 2008-07-31
DE50311502D1 (de) 2009-06-18
WO2004045618A2 (de) 2004-06-03
PT1562603E (pt) 2009-06-18
CO5570670A2 (es) 2005-10-31
DE10253282A1 (de) 2004-05-27
EA200500715A1 (ru) 2005-12-29
BE2014C016I2 (cs) 2023-03-07
IL167900A (en) 2013-06-27
BRPI0316264B8 (pt) 2021-05-25
LTC1562603I2 (lt) 2016-12-12
CA2506082C (en) 2011-06-21
HRP20050432A2 (en) 2006-06-30
KR20050075013A (ko) 2005-07-19
NL300650I2 (nl) 2017-11-02
CY1110500T1 (el) 2015-04-29
AU2003285326A1 (en) 2004-06-15
ECSP055774A (es) 2005-11-22
MXPA05005081A (es) 2005-07-01

Similar Documents

Publication Publication Date Title
FR14C0049I2 (fr) Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
CY2016031I1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
NO20044054L (no) Administrering av midler for behandling av betennelse
EP1510207A4 (en) THERAPEUTIC MEDICAMENT AGAINST DIABETES
EP1284728A4 (en) MEDICINES FOR TREATING ADDICTIC ADDICTION
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
DE60317887D1 (de) System zur verabreichung therapeutischer substanzen
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20033549L (no) Terapeutiske bindingsmolekyler
EP1534696A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDO MINIIDES
DE50308945D1 (de) Mehrschichtiges transmucosales therapeutisches system
ITMI20020773A1 (it) Farmaci per il trattamento dell'artrite
DK1553950T3 (da) Terapeutisk behandling
DE60321572D1 (de) Transdermales arzneimittelverabreichungssystem
EP1666046A4 (en) USE OF N-ACETYL-D-AMINOGLYCOSAMINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF CANCER AND METASTASES
EP1684756A4 (en) ZYTOKIN HEMMER FOR THE TREATMENT OF MAKULA DEGENERATION
EP1459754A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF CANCER
EP1485077A4 (en) DRUGS COMBINATION THERAPY
EP1475103A4 (en) MEANS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES
DE50313285D1 (de) Melatonin-tagesdosierungseinheiten
EP1712619A4 (en) MEANS FOR PREVENTING / CUREING CANCER
ITTO20020166U1 (it) Dispositivo terapeutico per il trattamento di sintomi provocati da malattie
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom